

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptasel1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:27:40 ON 11 FEB 2005

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:27:50 ON 11 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0
DICTIONARY FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10808889d.str




chain nodes :
10 11 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
6-11 8-10 10-12 11-13 13-14 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 6-11 7-8 8-9 8-10 10-12 11-13 13-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:28:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:28:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'REGISTRY' ENTERED AT 16:28:21 ON 11 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0
DICTIONARY FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10808889c.str



chain nodes :

10 11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

6-11 8-10 10-12 11-13 13-14

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

2-7 3-9 6-11 7-8 8-9 8-10 10-12 11-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS


11:CLASS 12:CLASS 13:CLASS 14:Atom

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 16:28:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s 14 full

FULL SEARCH INITIATED 16:28:45 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

0 ANSWERS

L6 0 SEA SSS FUL L4

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
161.76	323.30

FILE 'REGISTRY' ENTERED AT 16:29:29 ON 11 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

```
STRUCTURE FILE UPDATES:      9 FEB 2005  HIGHEST RN 828241-21-0
DICTIONARY FILE UPDATES:    9 FEB 2005  HIGHEST RN 828241-21-0
```

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

 \Rightarrow

Uploading C:\Program Files\Stnexp\Queries\10808889e.str



chain nodes :

10 11 12 13 14 15

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

6-11 8-10 10-12 11-13 13-14 14-15

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

2-7 3-9 6-11 7-8 8-9 8-10 10-12 11-13 13-14 14-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6


Match level :

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:CLASS
```

L7 STRUCTURE UPLOADED

$$\Rightarrow d$$

L7 HAS NO ANSWERS
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 17
SAMPLE SEARCH INITIATED 16:29:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 173 TO 747
PROJECTED ANSWERS: 3 TO 163

L8 3 SEA SSS SAM L7

=> s 17 full
FULL SEARCH INITIATED 16:29:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 308 TO ITERATE

100.0% PROCESSED 308 ITERATIONS 46 ANSWERS
SEARCH TIME: 00.00.01

L9 46 SEA SSS FUL L7

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 161.33 484.63

FILE 'CAPLUS' ENTERED AT 16:29:57 ON 11 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 9 Feb 2005 (20050209/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19

L10 1 L9


=> d ibib abs hitstr tot

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2003:259734 CAPLUS
DOCUMENT NUMBER: 138:271683
TITLE: Preparation of 2-(acylamino)-5-(benzenesulfonyloxy)benzimidazole compounds and their use for the treatment of cancer
INVENTOR(S): Clerc, Francois; Hamy, Francois; Depaty, Isabelle; Angouillan-Boniface, Odile; Roesner, Manfred
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPKDKW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1298125	A1	20030402	EP 2001-402460	20010926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003028721	A2	20030410	WO 2002-EP11353	20020926
WO 2003028721	A3	20031211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1432417	A2	20040630	EP 2002-772370	20020926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012856	A	20040914	BR 2002-12856	20020926
US 2005014811	A1	20050120	US 2004-80889	20040325
PRIORITY APPL. INFO.:			EP 2001-402460	A 20010926
			WO 2002-EP11353	W 20020926

OTHER SOURCE(S): MARPAT 138:271683
GI




AB New benzimidazole compds. of formula (I) [wherein R1 = 4-NH2, 4-alkylamino or cycloalkylamino eventually substituted with an acyl or its derivative, hydroxy, amino, alkoxy, heterocyclyl, or aryl group; R2 = (1) alkyl eventually substituted by amino, acid, acid derivative, alkoxy, aryl or OH

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-isobutylurea 503546-02-9P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(2-dimethylaminoethyl)urea 503546-03-0P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-ethylurea 503546-04-1P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(carboxymethyl)urea 503546-06-3P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(2-methoxyethyl)urea 503546-07-4P 503546-08-5P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(2-pyridylmethyl)urea 503546-09-6P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-cyclobutylurea 503546-10-9P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(4-pyridylmethyl)urea 503546-11-0P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-tert-butylurea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(acylamino)-5-(benzenesulfonyloxy)benzimidazole compds. as inhibitors of cyclin-dependent kinases for treatment of cancer)
RN 503545-56-0 CAPLUS
CN Benzenesulfonic acid, 4-[(2-hydroxyethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-58-2 CAPLUS
CN Benzenesulfonic acid, 4-[(2-hydroxyethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-60-6 CAPLUS
CN Benzenesulfonic acid, 4-[(2-methoxyethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)


L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
groups, (2) arylalkyl eventually substituted by alkoxy, halogeno, amino, acid or acid derivs., (3) alkoxy eventually substituted by aryl, (4) amino, HMR3, or NR34 (wherein R3, R4 = H, alkyl, alkylaryl, aryl or together form an alkylene chain) or pharmaceutically acceptable salts thereof, which are useful for treating cancer diseases, are prepd. These compds. I are inhibitors of cyclin-dependent kinases (CKDs, in particular CDK4) which are regulators for progression of the cell cycle at cell cycle checkpoints, and are effective in inhibiting the proliferation of neoplastic cells. Thus, 15.6 g 2-amino-5-(4-fluorophenylsulfonyloxy)nitro benzene were combined with 25 mL ethanolamine in 100 mL ethylene glycol in a round bottom flask and heated to reflux for 90 min to give, after workup, 15.5 g 2-amino-5-[(4-(2-hydroxyethyl)aminophenylsulfonyloxy)nitro]benzene (II). II (15.5 g) in 75 mL MeOH and 75 mL DMF were hydrogenated under atm. pressure with a catalytic amt. of Raney Nickel, filtered to remove the catalyst followed by washing the catalyst with MeOH. The filtrate and the washing were combined, concd. under reduced pressure, taken up in 150 mL MeOH and 30 mL glacial acetic acid, treated with 10.3 g 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea, and heated to reflux with stirring for 3 h to give, after crystn. from methanol, 7.4 g Me 5-[(4-(2-hydroxyethyl)aminophenylsulfonyloxy)benzimidazole-2-carbamate (III). III and Me 5-(4-aminophenylsulfonyloxy)benzimidazole-2-carbamate showed IC50 of 1.43 and 0.28 μM, resp., against CDK4/CyclinD1 kinase.

IT 503545-56-0P 503545-58-2P 503545-60-6P 503545-63-9P 503545-64-0P 503545-65-1P 503545-66-2P 503545-67-3P 503545-68-4P 503545-69-5P 503545-70-6P 503545-71-7P 503545-72-0P 503545-73-1P 503545-74-2P 503545-75-3P 503545-76-4P 503545-78-6P 503545-81-1P 503545-83-3P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]succinamic acid methyl ester 503545-84-4P, 4-[N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]carbamoyl]butanoic acid methyl ester 503545-85-5P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]cyclopropanecarboxamide 503545-86-6P 503545-87-7P 503545-89-9P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-methylurea 503545-90-2P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-dimethylurea 503545-91-3P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-cyclopropylurea 503545-92-4P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-isopropylurea 503545-93-5P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-butylurea 503545-95-7P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(2-fluorophenyl)urea 503545-96-8P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(3-chlorophenyl)urea 503545-97-9P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(4-methoxyphenyl)urea 503545-98-0P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(4-chlorophenyl)urea 503545-99-1P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(3-fluorophenyl)urea 503546-00-7P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(3-chlorophenyl)urea 503546-01-8P, N-[5-(4-


L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 503545-63-9 CAPLUS
CN Benzenesulfonic acid, 4-[(2-pyridinylmethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-64-0 CAPLUS
CN Benzenesulfonic acid, 4-(ethylamino)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-65-1 CAPLUS
CN Benzenesulfonic acid, 4-[(aminoacetyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-66-2 CAPLUS
CN Benzenesulfonic acid, 4-[(2-hydroxy-1-methylethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-67-3 CAPLUS
CN Benzenesulfonic acid, 4-[(2-hydroxypropyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-68-4 CAPLUS
CN Benzenesulfonic acid, 4-[(1-methylethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-69-5 CAPLUS
CN Benzenesulfonic acid, 4-[(1-(hydroxymethyl)propyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-70-8 CAPLUS
CN Benzenesulfonic acid, 4-(butylamino)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-75-3 CAPLUS
CN Benzenesulfonic acid, 4-[(2-(diethylamino)ethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-76-4 CAPLUS
CN Benzenesulfonic acid, 4-[(2-(tetrahydro-2-furanyl)methyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-78-6 CAPLUS
CN Benzenesulfonic acid, 4-[(2-phenylethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-81-1 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[1,1-dimethylethoxy]carbonyl]amino]acetyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-71-9 CAPLUS
CN Benzenesulfonic acid, 4-[(3-methoxypropyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-72-0 CAPLUS
CN Benzenesulfonic acid, 4-(methylamino)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-73-1 CAPLUS
CN Benzenesulfonic acid, 4-[(2-sulfoethyl)amino]-, 1-[2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl] ester (9CI) (CA INDEX NAME)




RN 503545-74-2 CAPLUS
CN Benzenesulfonic acid, 4-amino-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-83-3 CAPLUS
CN Butanoic acid, 4-[[5-[[[4-(cyclopentylamino)phenyl]sulfonyl]oxy]-1H-benzimidazol-2-yl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 503545-84-4 CAPLUS
CN Pentanoic acid, 5-[[5-[[[4-(cyclopentylamino)phenyl]sulfonyl]oxy]-1H-benzimidazol-2-yl]amino]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 503545-85-5 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503545-86-6 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[(methoxyacetyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 503545-87-7 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-
[[[(dimethylamino)acetyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503545-89-9 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-
[[[(methylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)



RN 503545-90-2 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-
[[[(dimethylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503545-91-3 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-
[[[(cyclopropylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503545-92-4 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(1-


L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 503545-98-0 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(4-
chlorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)



RN 503545-99-1 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(3-
fluorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503546-00-7 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-
chlorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503546-01-8 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-
methylpropyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)


L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methylethylamino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503545-93-5 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-
[[[(butylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX
NAME)



RN 503545-95-7 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-
fluorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503545-96-8 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(3-
methoxyphenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503545-97-9 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(4-
methoxyphenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 503546-02-9 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-
dimethylamino)ethyl]amino]carbonyl]amino]-1H-benzimidazol-5-yl ester
(9CI) (CA INDEX NAME)




RN 503546-03-0 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-
[[[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX
NAME)




RN 503546-04-1 CAPLUS
CN Glycine, N-[[[(5-[[[(4-(cyclopentylamino)phenyl)sulfonyl]oxy]-1H-
benzimidazol-2-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 503546-06-3 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-
methoxyethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA
INDEX NAME)




RN 503546-07-4 CAPLUS
 CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503546-08-5 CAPLUS
 CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[2-(pyridinylmethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503546-09-6 CAPLUS
 CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[2-(pyridinylmethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-10-9 CAPLUS
 CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[4-(pyridinylmethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)




RN 503546-11-0 CAPLUS
 CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[1,1-dimethylethyl]amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



IT 503545-77-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (reactant; preparation of
 2-(acylamino)-5-(benzenesulfonyloxy)benzimidazole
 compds. as inhibitors of cyclin-dependent kinases for treatment of
 cancer)

RN 503545-77-5 CAPLUS
 CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.39

490.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.73

-0.73

STN INTERNATIONAL LOGOFF AT 16:30:24 ON 11 FEB 2005